ABBV vs VRTV: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Veritiv Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-19.
AbbVie Inc. Β· Healthcare
$261.70
-1.0% upside to fair value
Med Conviction Grade C High Quality
VS
Veritiv Corporation Β· Industrials
$169.99
-45.0% upside to fair value
Med Conviction Grade D
QuantHub Verdict
ABBV has more upside to fair value (-1.0%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ABBV VRTV
Current Price $261.70 $169.99
Fair Value Estimate $259.04 $93.49
Upside to Fair Value -1.0% -45.0%
Market Cap $462.4B $2.3B
Forward P/E β€” β€”
EV / EBITDA 24.8x 5.4x
Price / Sales 7.2x 0.4x
Price / FCF 23.6x 10.4x
Revenue Growth YoY +10.2% -19.0%
Gross Margin 71.5% 22.7%
Operating Margin 29.3% 5.9%
Return on Equity -136.5% 48.6%
Dividend Yield 2.61% 1.48%
FCF Yield 4.25% 9.57%
Analyst Consensus Strong Buy Hold
Investment Thesis
ABBV β€” AbbVie Inc.
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
VRTV β€” Veritiv Corporation
Veritiv Corporation is a business-to-business distributor of specialty packaging, facility solutions, print, and publishing products, operating through four segments with a network of distribution centers and roughly 5,000 employees. The business quality is mixed: it generates a strong 48.6% ROE and trades at a low 7.13 trailing P/E and 5.44 EV/EBITDA, but revenue declined 19.0% year over year in…
Accumulation Zones
Metric ABBV VRTV
Zone Low $194.28 $70.12
Zone High $220.18 $79.47
In Buy Zone? No No
← ABBV Research    VRTV Research β†’    All Research